Next Article in Journal
Clinical Practice Guidelines in Breast Cancer
Previous Article in Journal
Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: Redrawing the Lines
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on as a courtesy and upon agreement with Multimed Inc..
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:

Advances in the Systemic Treatment of Triple-Negative Breast Cancer

Dr. H. Bliss Murphy Cancer Centre, Memorial University of Newfoundland, 300 Prince Philip Drive, Saint John’s, NL A1B 3V6, Canada
Author to whom correspondence should be addressed.
Curr. Oncol. 2018, 25(s1), 142-150;
Submission received: 3 March 2018 / Revised: 6 April 2018 / Accepted: 8 May 2018 / Published: 1 June 2018


Triple-negative breast cancer constitutes a heterogeneous group of malignancies that are often aggressive and associated with a poor prognosis. Molecular characterization, while not a standard of care, can further subtype triple-negative breast cancer and provide insight into prognostication and behaviour. Optimal chemotherapy regimens have yet to be established; however, there have been advances in the systemic treatment of triple-negative breast cancer in the neoadjuvant, adjuvant, and metastatic settings. In this review, we discuss evidence for the potential benefit of neoadjuvant platinum-based chemotherapy, adjuvant combination chemotherapy with weekly paclitaxel, and BRCA mutation–directed therapy in the metastatic setting. The role for adjuvant capecitabine in patients who do not achieve a pathologic complete response with neoadjuvant chemotherapy is reviewed. Future directions and data concerning novel targeted agents are reviewed, including the most recent data on parp [poly (ADP-RIBOSE) polymerase] inhibitors, antiandrogen agents, and immunotherapy.
Keywords: breast cancer; triple-negative breast cancer breast cancer; triple-negative breast cancer

Share and Cite

MDPI and ACS Style

Lebert, J.M.; Lester, R.; Powell, E.; Seal, M.; McCarthy, J. Advances in the Systemic Treatment of Triple-Negative Breast Cancer. Curr. Oncol. 2018, 25, 142-150.

AMA Style

Lebert JM, Lester R, Powell E, Seal M, McCarthy J. Advances in the Systemic Treatment of Triple-Negative Breast Cancer. Current Oncology. 2018; 25(s1):142-150.

Chicago/Turabian Style

Lebert, J.M., R. Lester, E. Powell, M. Seal, and J. McCarthy. 2018. "Advances in the Systemic Treatment of Triple-Negative Breast Cancer" Current Oncology 25, no. s1: 142-150.

Article Metrics

Back to TopTop